Opthea Ltd has released a press release.
Opthea Receives FDA Waiver for Pediatric Study Plan
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Opthea
- Opthea Treats First Patient in Phase 3 Trials of OPT-302
- Opthea Finalizes Ph 3 Study Designs and Startup Activities
- Opthea Receives A$8.5m R&D Tax Incentive
- Opthea Announces Closing of US Initial Public Offering
- Opthea Announces Pricing of US Initial Public Offering
Later from Opthea
- Optheas OPT-302 Granted Fast-Track for wet AMD
- Opthea reports Fiscal Year 2021 Results and Highlights
- Optheas Phase 3 open for patient recruitment in Europe
- Opthea Corporate Presentation - October 2021
- Opthea opens patient enrollment in the Asia-Pacifi Region
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea